Tonix Pharmaceuticals Holding Corp (TNXP)

Nov 9, 2026

Tonix Pharmaceuticals announced its financial results for the third quarter of 2026, reporting approximately $15 million in net sales for TONMYA®, a 37% increase from the previous quarter. The company also highlighted its strong cash position of $163 million and strategic focus on expanding TONMYA's market presence, while advancing its core clinical programs for major depressive disorder, Lyme disease prevention, and kidney transplant rejection. Despite a net loss of $53.3 million for the quarter, Tonix increased its sales force and expanded payer access for TONMYA.

Nov 2, 2026

Tonix Pharmaceuticals has appointed George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation, effective October 30, 2026. In this role, Lederman will lead AI initiatives to enhance operational efficiency and manage costs, as well as oversee business development, including evaluating partnerships and licensing opportunities to advance clinical programs and share development costs. Dr. Lederman brings extensive experience from Aliaxis and McKinsey & Company, where he focused on corporate strategy, operational transformation, and applied artificial intelligence.